Literature DB >> 21806335

The clinical and therapeutic implications of cancer stem cell biology.

Liang Cheng1, Riley Alexander, Shaobo Zhang, Chong-Xian Pan, Gregory T MacLennan, Antonio Lopez-Beltran, Rodolfo Montironi.   

Abstract

Cancer stem cells (CSCs) have provided new insights into the tumorigenesis and metastatic potential of cancer. The discovery of CSCs has provided many new insights into the complexities of cancer therapy: tumor initiation, treatment resistance, metastasis, recurrence, assessment of prognosis and prediction of clinical course. Recent rapid advances in molecular analysis have contributed to the better understanding of the molecular attributes and pathways that give CSCs their unique attributes. Use of these molecular techniques has facilitated elucidation of specific surface markers and pathways that favor propagation of CSCs - allowing for targeted therapy. Furthermore, it has been discovered that a specific microenvironment, or niche, is essential for the genesis of tumors from CSCs. Therapeutic strategies that alter these microenvironments compromise CSC proliferation and constitute another method of targeted cancer therapy. We review the clinical and therapeutic implications of CSCs, with a focus on treatment resistance and metastasis, and the emerging approaches to target CSCs and their microenvironments in order to attain improved outcomes in cancer. It is noteworthy that CSCs are the only cells capable of sustaining tumorigenesis; however, the cell of origin of cancer, in which tumorigenesis is initiated, may be distinct from CSCs that propagate the tumor.

Entities:  

Mesh:

Year:  2011        PMID: 21806335     DOI: 10.1586/era.11.82

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  13 in total

1.  Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells.

Authors:  Lei Zhang; Yong Yan; Ying Jiang; Jun Qian; Lei Jiang; Guohan Hu; Yicheng Lu; Chun Luo
Journal:  Oncol Lett       Date:  2017-08-04       Impact factor: 2.967

2.  Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.

Authors:  Ayako Nakano; Hirokazu Miki; Shingen Nakamura; Takeshi Harada; Asuka Oda; Hiroe Amou; Shiro Fujii; Kumiko Kagawa; Kyoko Takeuchi; Shuji Ozaki; Toshio Matsumoto; Masahiro Abe
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

3.  Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.

Authors:  Cathy C Zhang; Zhengming Yan; Qing Zong; Douglas D Fang; Cory Painter; Qin Zhang; Enhong Chen; Maruja E Lira; Annette John-Baptiste; James G Christensen
Journal:  Stem Cells Transl Med       Date:  2013-02-13       Impact factor: 6.940

Review 4.  Oligometastases: the new paradigm and options for radiotherapy. A critical review.

Authors:  H Badakhshi; A Grün; C Stromberger; V Budach; D Boehmer
Journal:  Strahlenther Onkol       Date:  2013-03-21       Impact factor: 3.621

5.  Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line.

Authors:  Naoki Wada; Maosheng Zhan; Yumiko Hori; Keiichiro Honma; Jun-ichiro Ikeda; Eiichi Morii
Journal:  Lab Invest       Date:  2013-11-04       Impact factor: 5.662

Review 6.  Chemoquiescence for ideal cancer treatment and prevention: where are we now?

Authors:  Napapan Kangwan; Jong-Min Park; Eun-Hee Kim; Ki Baik Hahm
Journal:  J Cancer Prev       Date:  2014-06

7.  DNA alterations in Cd133+ and Cd133- tumour cells enriched from intra-operative human colon tumour biopsies.

Authors:  Diana Cervantes-Madrid; Yvonne Wettergren; Peter Falk; Kent Lundholm; Annika G Asting
Journal:  BMC Cancer       Date:  2017-03-27       Impact factor: 4.430

Review 8.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Authors:  Alberto M Martelli; Francesca Chiarini; Camilla Evangelisti; Alessandra Cappellini; Francesca Buontempo; Daniela Bressanin; Milena Fini; James A McCubrey
Journal:  Oncotarget       Date:  2012-04

9.  Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts.

Authors:  Giovanni Sette; Katia Fecchi; Valentina Salvati; Fiorenza Lotti; Emanuela Pilozzi; Enrico Duranti; Mauro Biffoni; Alfredo Pagliuca; Daniela Martinetti; Lorenzo Memeo; Michele Milella; Ruggero De Maria; Adriana Eramo
Journal:  J Exp Clin Cancer Res       Date:  2013-11-16

10.  Sphere-forming-like cells (squamospheres) with cancer stem-like cell traits from VX2 rabbit buccal squamous cell carcinoma.

Authors:  Yuk-Kwan Chen; Anderson Hsien-Cheng Huang; Li-Min Lin
Journal:  Int J Oral Sci       Date:  2014-07-11       Impact factor: 6.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.